Skip to main content
EDIT $1.70 -0.58%
EDIT logo
EDIT · Editas Medicine, Inc.
Track EDIT — free
$1.70 -0.01 (-0.58%) Q2 2024 earnings call transcript
Market Cap
$263.92M
Shares
154.34M
Volume · Nov 19 1.93M Avg daily vol (3M) 2.65M
All webcasts

Earnings call · FY2026 Q3

Editas Medicine, Inc. (EDIT) Q3 2026 Earnings Call

Concluded Nov 9, 2026
Nov 9, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $10.37M +37.4% YoY
Diluted EPS -$0.15
Net income -$23.39M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 9, 2026
Editas Medicine received HREC approval and completed TGA notification for the Phase 1/2 Strive study of EDIT-401 in Australia, with dosing planned this year. Cash and marketable securities totaled $190.2 million, supporting a runway into the second half of 2028.
10-Q report · filed Nov 9, 2026
Editas Medicine received approval in October 2026 to initiate the Strive trial of EDIT-401 in Australia, with dosing on track for 2026. Net loss was $66.6 million for the nine months ended September 30, 2026, versus $154.4 million in 2025.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document